UNSPSC 51285314: Nifurizone

This classification denotes an anti-infective agent with the molecular formula C12H13N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 26LO5Z6IHQ, chemically known as 1-imidazolidinecarboxamide, n-methyl-3-((3-(5-nitro-2-furyl)allylidene)amino)-2-oxo- but more generally known as nifurizone, which bears US NIH Compound Identifier 9577579. European Medicines Agency schedules Nifurizone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09267MIG.

UNSPSC 51285314 Nifurizone, a Commodity code, nominally describes a specific antimicrobial pharmaceutical active ingredient, but recent state and local solicitations tagged with this code show little relevant procurement activity aligned to nifurizone itself. The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC for doxycycline hyclate and ciprofloxacin hydrochloride tablets—neither nifurizone. Seminole County, Florida solicited naloxone and safe drug deactivation systems, also unrelated to the code's nominal scope. State and local buyers appear to use this code inconsistently or as a catchall for pharmaceutical supply chain activity rather than as a precise descriptor of nifurizone procurement.

Geographic activity centers on Illinois and Florida based on the recent opportunities. The Illinois Department of Public Health contract, awarded August 28, 2026 with a total value of $2,999,999.11 over a 12-month initial term plus two renewal years, represents the larger by-value opportunity. Seminole County, Florida's IFB 60459723LAS, posted June 30, 2026 with a July 26, 2026 response deadline, sought annual supply of 1,900 naloxone units and 800 deactivation systems with quarterly deliveries and a two-year initial term plus one-year renewal option. Both procurements were awarded or posted through competitive sealed bidding (IFB) processes. The code's recent activity is sparse and misaligned with its pharmaceutical name—vendors pursuing opportunities tagged here should verify scope against the actual RFP or IFB documents rather than assume nifurizone-specific demand.